Patient Population

This cross-sectional study used data from the PRIME-FFR population (n = 1983), which resulted from the merger of the R3F (October 2008-June 2010) and POST-IT cohorts (March 2012-November 2013).^5,7,8 These nationwide prospective studies shared a common design and objective dedicated to investigating the routine use of FFR at the time of diagnostic angiography and its association with patient management decisions and 1-year clinical outcomes. A total of 1983 patients were referred for coronary angiography in 40 European centers and prospectively included in the registries. The R3F and POST-IT studies were approved by the relevant institutional review boards or ethics committees. The R3F study was also approved by the Commission National Informatique et Liberté. All patients provided written informed consent to clinical follow-up and to storage and use of their clinical data. All data had been deidentified before storage.

In both studies, baseline clinical and angiographic measures were prospectively recorded in dedicated electronic case report forms. Inclusion and exclusion criteria for each of the original registries and definition of clinical characteristics (including diabetes) are provided in the eMethods in the Supplement.